Table 2.

Pharmacokinetic parameters following single doses of RN317 or bococizumab in subjects with hypercholesterolemia receiving ongoing statin therapy

	RN317							Bococizumab
	s.c.	s.c.	s.c.	s.c.	i.v.	i.v.	i.v.	s.c.	s.c.	i.v.
	0.3 mg/kg	1 mg/kg	3 mg/kg	6 mg/kg	1 mg/kg	3 mg/kg	6 mg/kg	1 mg/kg	3 mg/kg	1 mg/kg
	(n = 6)	(n = 12)	(n = 16)	(n = 6)	(n = 11)	(n = 6)	(n = 6)	(n = 12)	(n = 16)	(n = 6)
n *	6	12	16	6	11	6	6	12	16	6
Cmax, μg/ml	1.172	3.099	11.09	23.02	35.7	86.01	157.8	1.824	11.85	35.89
	(20)	(33)	(35)	(28)	(195)	(12)	(9)	(65)	(66)	(12)
Tmax, h	253	253	120	72	2.0	2.51	2.00	156	72.0	1.50
	(143–339)	(72–504)	(24–672)	(72–337)	(0.967–4.00)	(1.00–4.00)	(1.00–3.00)	(48.0–171)	(4.00–168)	(1.00–4.00)
N*	2	8	16	6	11	6	6	1	10	6
AUCinf, μg.h/ml	NR	3,103	7,995	18,100	6,705	19,420	29,220	NR	3,721	3,451
		(30)	(32)	(30)	(22)	(13)	(6)		(47)	(13)
t1/2, days	NR	20.88 ± 4.33	19.40 ± 5.40	18.58 ± 4.1	19.49 ± 6.43	17.52 ± 2.9	14.63 ± 4.68	NR	8.378 ± 2.656	3.400 ± 0.692

Data shown are geometric mean (coefficient of variation; %CV) for all parameters except for T_max where median (min, max) is shown, and t_1/2 where arithmetic mean ± SD is shown.

*n is the number of subjects in the treatment group and contributing to the mean; N is the number of subjects with a well‐characterized terminal phase. AUC_inf, area under the plasma concentration–time curve from time zero to infinity; C_max, maximum concentration; NR, not reported where <3 subjects had reportable parameter values; SD, standard deviation; t_1/2, terminal half‐life; T_max, time to reach maximum concentration.